These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 24338893)

  • 1. Semiparametric methods for multistate survival models in randomised trials.
    Hudson HM; Lô SN; Simes RJ; Tonkin AM; Heritier S
    Stat Med; 2014 May; 33(10):1621-45. PubMed ID: 24338893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology.
    Nelson CL; Sun JL; Tsiatis AA; Mark DB
    Stat Med; 2008 Nov; 27(26):5525-55. PubMed ID: 18613251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
    Sun X; Li X; Chen C; Song Y
    J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A semi-Markov model for multistate and interval-censored data with multiple terminal events. Application in renal transplantation.
    Foucher Y; Giral M; Soulillou JP; Daures JP
    Stat Med; 2007 Dec; 26(30):5381-93. PubMed ID: 17987670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of different parametric proportional hazards models for interval-censored data: a simulation study.
    Gong Q; Fang L
    Contemp Clin Trials; 2013 Sep; 36(1):276-83. PubMed ID: 23916917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size calculation for the weighted rank statistics with paired survival data.
    Jung SH
    Stat Med; 2008 Jul; 27(17):3350-65. PubMed ID: 18205148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
    Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
    Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An EM-based semi-parametric mixture model approach to the regression analysis of competing-risks data.
    Ng SK; McLachlan GJ
    Stat Med; 2003 Apr; 22(7):1097-111. PubMed ID: 12652556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semiparametric models for cumulative incidence functions.
    Bryant J; Dignam JJ
    Biometrics; 2004 Mar; 60(1):182-90. PubMed ID: 15032788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.
    Geskus RB
    Biometrics; 2011 Mar; 67(1):39-49. PubMed ID: 20377575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models.
    Cope S; Ouwens MJ; Jansen JP; Schmid P
    Value Health; 2013; 16(2):403-17. PubMed ID: 23538193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyses of cumulative incidence functions via non-parametric multiple imputation.
    Ruan PK; Gray RJ
    Stat Med; 2008 Nov; 27(27):5709-24. PubMed ID: 18712779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample sizes for clinical trials with time-to-event endpoints and competing risks.
    Schulgen G; Olschewski M; Krane V; Wanner C; Ruf G; Schumacher M
    Contemp Clin Trials; 2005 Jun; 26(3):386-96. PubMed ID: 15911472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tests for treatment group differences in the hazards for survival, before and after the occurrence of an intermediate event.
    Bebchuk JD; Betensky RA
    Stat Med; 2005 Feb; 24(3):359-78. PubMed ID: 15568187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.
    Kombrink K; Munk A; Friede T
    Stat Med; 2013 Aug; 32(18):3055-66. PubMed ID: 23508697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interval-censored time-to-event and competing risk with death: is the illness-death model more accurate than the Cox model?
    Leffondré K; Touraine C; Helmer C; Joly P
    Int J Epidemiol; 2013 Aug; 42(4):1177-86. PubMed ID: 23900486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis for aggregated survival data with competing risks: a parametric approach using cumulative incidence functions.
    Bonofiglio F; Beyersmann J; Schumacher M; Koller M; Schwarzer G
    Res Synth Methods; 2016 Sep; 7(3):282-93. PubMed ID: 26387882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)--a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness.
    Markwood TT; Kent SM; Coyle LC; Flaherty PJ; O'Malley PG; Taylor AJ
    Am Heart J; 2001 Mar; 141(3):342-7. PubMed ID: 11231429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexible multistate models for interval-censored data: Specification, estimation, and an application to ageing research.
    Machado RJM; van den Hout A
    Stat Med; 2018 May; 37(10):1636-1649. PubMed ID: 29383740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.